Renal disease in HIV-infected individuals

Current Opinion in HIV and AIDS

Volumn 6, Issue 4, 2011, Pages 285-289

  Phair, John ^a   Palella, Frank ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Effects of antiretroviral drugs upon renal function; estimates of glomerular filtration; HIV associated nephropathy; renal transplantation of HIV infected patients with endstage renal disease

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIRETROVIRUS AGENT; ATAZANAVIR; INDINAVIR; LOPINAVIR PLUS RITONAVIR; RALTEGRAVIR; TENOFOVIR; VICRIVIROC;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DIABETES MELLITUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED NEPHROPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY TRANSPLANTATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; TUBULAR DYSFUNCTION;

AIDS-ASSOCIATED NEPHROPATHY; ANTI-HIV AGENTS; HEPATITIS C; HIV INFECTIONS; HUMANS; INCIDENCE;

EID: 79959361389     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283476bc3     Document Type: Review

References (45)

1. Adih WK, Selik RM, Hu X. Trends in diseases reported on US Death Certificates that mentioned HIV infection, 1996-2006. J Int Assoc Physicians AIDS Care 2011; 10:5-11. Multiple-cause mortality was determined from review of death certificates mentioning HIV. Liver disease, renal disease, and heart disease were prominent non-AIDS causes of death.
2. Belloso WH, Orellana LC, Grinsztejn B, et al. Analysis of serious non-AIDS events among HIV-infected adults at Latin American sites. HIV Med 2010; 11:554-564.
3. Smith C, Sabin CA, Lundgren JD, et al. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010; 24:1537-1548.
4. Lucas GM, Clarke W, Kagaayi J, et al. Decreased kidney function in a community-based cohort of HIV-Infected and HIV-negative individuals in Rakai, Uganda. J Acquir Immune Defic Syndr 2010; 55:491-494. Estimated GFR was determined among HIV-infected and uninfected individuals in a cohort in Rakai, before antiretroviral therapy was started. The HIV infected were twice as likely to have evidence of mild or moderate reduction in GFR, although moderately impaired renal function was uncommon as measured by the MDRD equation.
5. Stenvinkel P. Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. J Intern Med 2010; 268:456-467. Kidney disease is a silent epidemic. The global increase in hypertension, obesity, and diabetes requires that effective strategies must be developed to control CKD and reduce cardiovascular risk.
6. Hemmelgarn BR, Manns BJ, Lloyd A, et al. Relation between kidney function, proteinuria, and adverse outcomes. JAMA 2010; 303:423-429. All-cause mortality was increased in an analysis of outcomes among close to a million uninfected individuals in Alberta, Canada. Mortality was higher in those with lower eGFR and/or proteinuria.
7. Choi AI, Li Y, Parikh C, et al. Long-term clinical consequences of acute kidney injury in the HIV-infected. Kidney Int 2010; 78:478-485. Acute kidney injury in HIV-infected individuals was associated with progression of renal disease and death but not CVD.
8. Choi A, Scherzer R, Bacchetti P, et al. Cystatin C, albuminuria, and 5-year allcause mortality in HIV-infected persons. Am J Kidney Dis 2010; 56:872-882. A large study using cystatin c to determine eGFR which demostrated that reduced GFR and/or albuminuria was associated with increased mortality. The 5-year follow-up adds to the relevance of this study.
9. Estrella MM, Parekh RS, Abraham A, et al. The impact of kidney function at highly active antiretroviral therapy initiation on mortality in HIV-infected women. J Acquir Immune Defic Syndr 2010; 55:217-220. In the Women's Interagency HIV Study, a large prospective cohort investigation, renal function at initiation of HAART was an independent predictor of death, especially in women with AIDS.
10. George E, Lucas GM, Nadkarni GN, et al. Kidney function and the risk of cardiovascular events in HIV-1-infected patients. AIDS 2010; 24:387-394. Investigators at the Johns Hopkins HIV clinic determined that decreased renal function was associated with CVD as compared with HIV infected without evidence of CVD. Reduced renal function was an independent determinant of CVD after controlling for traditional risk factors for CVD.
11. Post FA, Wyatt CM, Mocroft A. Biomarkers of impaired renal function. Curr Opin HIV AIDS 2010; 5:524-530. The authors thoroughly reviewed the literature discussing indirect and direct measures on GFR and tubular function in HIV-infected individuals. They concluded that further studies are needed to determine the best method of detecting and monitoring renal disease in this population.
12. Tonelli M, Muntner P, Lloyd A, et al. Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: a cohort study. Ann Intern Med 2011; 154:12-21. A major analysis of the value of adding measures of albuminuria or proteinuria to eGFR in order to determine risk of progression to CKD among close to 500 000 non-HIV-infected persons in Alberta. Two independent validation cohorts were used to compare the five-category risk system. Higher risk of progression of renal disease was associated with lower eGFR or increase proteinuria.
13. Levey AS, Tangri N, Stevens LA. Classification of chronic kidney disease: a step forward. Ann Intern Med 2011; 154:65-67.
14. Gopalakrishnan I, Iskandar SS, Daeihagh P, et al. Coincident idiopathic focal segmental glomerulosclerosis collapsing variant and diabetic nephropathy in an African American homozygous for MYH9 risk variants. Hum Pathol 2011; 42:291-294. This is a comprehensive review of the interaction of HIV and renal cells. The authors emphasize African descent, the MYH9 susceptible allele and activation of the renin-angiotensin-aldosterone system as the important factors in the development of HIVAN. The authors review renal biopsy studies from patients with HIVAN and the potential portals of entry of HIV into renal cells.
15. Mikulak J, Singhal PC. HIV-1 and kidney cells: better understanding of viral interaction. Nephron Exp Nephrol 2010; 115:e15-e21.
16. Nelson GW, Freedman BI, Bowden DW, et al. Dense mapping of MYH9 localizes the strongest kidney disease associations to the region of introns 13 to 15. Hum Mol Genet 2010; 19:1805-1815.
17. Murea M, Freedman BI. Essential hypertension and risk of nephropathy: a reappraisal. Curr Opin Nephrol Hypertens 2010; 19:235-241.
18. Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329:841-845. The authors have identified that focal segmental glomerulosclerosis and hypertension in African-Americans are associated with a variant of genes encoding a serum factor, apolipoprotein L-1 that lyses trypanosomes. Only serum from persons with the kidney-associated variant lyse T. brucei. This study provides a plausible biologic rationale for the selection of this genotype in persons of African descent and an explanation for the occurrence of HIVAN in persons of African descent.
19. Genovese G, Tonna SJ, Knob AU, et al. A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containing APOL1 and MYH9. Kidney Int 2010; 78:698-704. A further analysis demonstrating that variants within a 60-kb region of chromosome 22 contained both APOL1 and MHY9 genes associated with glomerulosclerosis in African-Americans.
20. Tzur S, Rosset S, Shemer R, et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 2010; 128:345-350. Another study that identifies two west African-specific missence mutations in the neighboring APOL1 gene that are more strongly associated with ESRDs than the MYH9 gene.
21. Szczech LA. Tackling the unknowns in HIV-related kidney diseases. N Engl J Med 2010; 363:2058-2059. An editorial which concisely reviews the status of our knowledge of renal disease in HIV-infected persons.
22. Mikulak J, Teichberg S, Arora S, et al. DC-specific ICAM-3-grabbing non-integrin mediates internalization of HIV-1 into human podocytes. Am J Physiol Renal Physiol 2010; 299:F664-F673. An important investigation which examines the possible mechanisms of the interaction of HIV with renal cells.
23. Khatua AK, Taylor HE, Hildreth JE, et al. Nonproductive HIV-1 infection of human glomerular and urinary podocytes. Virology 2010; 408:119-127.
24. Sharma M, Callen S, Zhang D, et al. Activation of Notch signaling pathway in HIV- associated nephropathy. AIDS 2010; 24:2161-2170.
25. Izzedine H, Acharya V, Wirden M, et al. Role of HIV-1 DNA levels as clinical marker of HIV-1-associated nephropathies. Nephrol Dial Transplant 2011; 26:580-583. The authors note that HIV-1 DNA determines the occurrence of HIVAN.
26. Operskalski EA, Kovacs A. HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep 2011; 8:12-22. A thorough evaluation of the clinical problems associated with HIV/HCV co-infection.
27. Fischer MJ, Wyatt CM, Gordon K, et al. Hepatitis C and the risk of kidney disease and mortality in veterans with HIV. J Acquir Immune Defic Syndr 2010; 53:222-226. The impact of HIV/HCV co-infection upon the development of CKD in a large cohort of veterans is reviewed. The study documents the increased risk of CVD and mortality in persons with CKD associated with HIV/HCV infection.
28. Izzedine H, Sene D, Cacoub P, et al. Kidney diseases in HIV/HCV-co-infected patients. AIDS 2009; 23:1219-1226.
29. Nourse PJ, Cotton MF, Bates WD. Renal manifestations in children co-infected with HIV and disseminated tuberculosis. Pediatr Nephrol 2010; 25:1759-1763.
30. Cooper RD, Wiebe N, Smith N, et al. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010; 51:496-505. This analysis concludes that although administration of tenofovir is followed by a decreased eGFR, the clinical consequences are modest.
31. Deti EK, Thiebaut R, Bonnet F, et al. Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France. HIV Med 2010; 11:308-317. The authors review the effect of tenofovir and other antiretroviral agents upon renal function in the large cohort of HIV-infected French individuals.
32. De Beaudrap P, Diallo MB, Landman R, et al. Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215). AIDS Res Hum Retroviruses 2010; 26:1221-1227. These authors noted a moderate decline in eGFR with tenofovir therapy. One year postdiscontinuation one-third had persistence of the decreased GFR.
33. Wever K, van Agtmael MA, Carr A. Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men. J Acquir Immune Defic Syndr 2010; 55:78-81. Another report of the failure of renal function to completely return to normal following discontinuation of tenofovir.
34. Mocroft A, Kirk O, Reiss P, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010; 24:1667-1678. The experience of the EuroSIDA cohort with CKD in association with the use of antiretroviral agents is reviewed in this publication.
35. Rodriguez-Novoa S, Alvarez E, Labarga P, Soriano V. Renal toxicity associated with tenofovir use. Expert Opin Drug Saf 2010; 9:545-559.
36. Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 2009; 23:689-696.
37. Judd A, Boyd KL, Stohr W, Dunn D, et al. Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study. AIDS 2010; 24:525-534.
38. Masia M, Enriquez R, Sirvent A, Gutierrez F, et al. Severe acute renal failure associated with rhabdomyolysis during treatment with raltegravir: a call for caution. J Infect 2010; 61:189-190.
39. Molto J, Sanz-Moreno J, Valle M, et al. Minimal removal of raltegravir by hemodialysis in HIV-infected patients with end-stage renal disease. Antimicrob Agents Chemother 2010; 54:3047-3048.
40. Kasserra C, Sansone-Parsons A, Keung A, et al. Renal insufficiency has no effect on the pharmacokinetics of vicriviroc in a ritonavir-containing regimen. Clin Pharmacokinet 2010; 49:397-406.
41. Arendse CG, Wearne N, Okpechi IG, Swanepoel CR. The acute, the chronic and the news of HIV-related renal disease in Africa. Kidney Int 2010; 78:239-245.
42. + T-cell number and higher HIV-RNA levels.
43. Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med 2010; 363:2004-2014. This important study documents the results of renal transplantation in selected HIV-infected individuals with ESRD. The authors compared results to transplantation in non-HIV-infected persons above the age of 65 years. Mortality and graft survival were comparable in the recipients of renal grafts to historical controls but graft rejection occurred more commonly.
44. Reese PP, Tehrani T, Lim MA, et al. Determinants of the decision to accept a kidney from a donor at increased risk for blood-borne viral infection. Clin J Am Soc Nephrol 2010; 5:917-923.
45. Formica RN Jr, Asch WS, Wagner KR, Kulkarni S. Kidney transplantation and HIV: does recipient privacy outweigh the donor's right to information? Clin J Am Soc Nephrol 2010; 5:924-928.